Related Experiment Video
Updated: Sep 12, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
THE BIOLOGY BEHIND PD-1 CHECKPOINT BLOCKADE
1Boston, MA.
Abstract:
Programmed death 1 (PD-1) pathway inhibitors have transformed cancer therapy, leading to durable responses in some patients. However, many patients do not benefit from PD-1 blockade therapy, which highlights the critical need to identify new therapeutic targets to complement PD-1 pathway inhibitors. To address this need, we have developed an in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based screening platform to discover novel regulators of anti-tumor immunity. In this article, I will first discuss the biology of the PD-1 pathway and its role in regulating anti-tumor immunity. Next, I will introduce our innovative CRISPR-based platforms designed for conducting gene screens in mature immune cell lineages and for enabling gene perturbation without stimulating or manipulating immune cells, two approaches that can affect immune cell development and function. In addition, I will illustrate how these platforms facilitate discovery of new targets that can promote anti-tumor immunity and their potential to lead to more effective cancer therapies.
Insights
New CRISPR screening platforms identify novel targets to enhance anti-tumor immunity, complementing programmed death 1 (PD-1) pathway inhibitors for improved cancer therapy. These tools enable gene discovery in immune cells without manipulation, advancing cancer treatment strategies.
Area of Science:
- Immunology
- Genetics
- Oncology
Background:
- Programmed death 1 (PD-1) pathway inhibitors have revolutionized cancer therapy, but limited patient response necessitates new therapeutic targets.
- Identifying novel regulators of anti-tumor immunity is crucial to enhance the efficacy of current immunotherapies.
Purpose of the Study:
- To develop and utilize innovative in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based screening platforms.
- To discover novel regulators of anti-tumor immunity that can complement PD-1 blockade therapy.
Main Methods:
- Development of CRISPR-based platforms for gene screening in mature immune cell lineages.
- Implementation of gene perturbation techniques without immune cell stimulation or manipulation to preserve cell function.
- Application of these platforms to identify new targets promoting anti-tumor immunity.
Main Results:
- The study introduces novel CRISPR screening platforms for immune cell research.
- These platforms facilitate the discovery of previously unknown regulators of anti-tumor immune responses.
- The identified targets hold potential for developing more effective cancer therapies.
Conclusions:
- The developed CRISPR platforms offer innovative approaches for discovering therapeutic targets in cancer immunology.
- These findings pave the way for next-generation cancer immunotherapies that overcome resistance to PD-1 blockade.
- Further research utilizing these platforms can significantly advance the field of immuno-oncology.
